22 results about "Cycloalternan" patented technology

The present invention relates to a method for producing unsubstituted or at least monosubstituted α,ω-dicarboxylic acids or ketocarboxylic acids and unsubstituted or at least monosubstituted cycloalkanones by electrochemically oxidizing unsubstituted or at least monosubstituted mono- or polyunsaturated cycloalkenes and unsubstituted or at least monosubstituted saturated alicyclic hydrocarbons in an electrolytic cell in the presence of inorganic or organic nitrates in a reaction medium in the presence of oxygen.

A process produces unsubstituted or at least singly substituted cycloalkanones by electrochemical oxidation of unsubstituted or at least singly substituted, saturated cycloaliphatic hydrocarbons in the presence of an inorganic or organic nitrate salt in an electrolysis cell in a reaction medium in the presence of oxygen.

Disclosed in the present invention are a PARP1 / CDK6 dual-target inhibitor, and a preparation method therefor and the use thereof. The PARP1 / CDK6 dual-target inhibitor is a compound having a structure represented by formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from or , and R is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, sulfhydryl, cyano, nitro, methoxy, a C1-C8 alkyl, or a C3-C8 cycloalkyl. The PARP1 / CDK6 dual-target inhibitor of the present invention exhibits good effects against human breast cancer cells, and maintains a good in vitro enzyme inhibitory activity against CDK6 and PARP1. Disclosed in the present invention is the use of a CDK6 / BRD4 dual-target inhibitor in the preparation of a drug for treating PARP1 / CDK6-mediated diseases. Disclosed in the present invention is the use of a PARP1 / CDK6 dual-target inhibitor in the preparation of a drug for treating or preventing triple-negative breast cancer.

A process produces unsubstituted or at least monosubstituted α,ω-dicarboxylic acids or ketocarboxylic acids and unsubstituted or at least monosubstituted cycloalkanones by electrochemical oxidation of unsubstituted or at least monosubstituted, monounsaturated or poly unsaturated cycloalkenes and unsubstituted or at least monosubstituted, saturated cycloaliphatic hydrocarbons in the presence of an inorganic or organic nitrate salt in an electrolysis cell in a reaction medium in the presence of oxygen.

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof.wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

A compound having formula I: R1 is hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic, aryl, heteroaryl, -NR7R8, -CO-R 10 or -NH-CO-R 10 L is a bond, a heterocyclic divalent group, a heteroaromatic divalent group, or an aromatic divalent group; M is a bond, an alkyl group, an aryl group, a heterocyclic divalent group, a heteroaromatic divalent group, or an aromatic divalent group; X is a bond, -O-, -S-, -SO2-, -CO-, -NR9-, -(CH2)m-, or a heterocyclic divalent group, where m is 1, 2, 3, 4, 5, or 6; Y is a bond, -NH-, a heterocyclic divalent group, a heteroaromatic divalent group, a divalent benzyl group, or an aromatic divalent group; and Z is hydrogen, halogen, alkyl, aryl, heterocyclic, heteroaromatic, -NR7R8, -CO-R 10 or -NH-CO-R 10 R7, R8, and R9 are independently hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic, or heteroaryl; and R 10 It can be -O-tert-butyl, -CH2CH2-phenyl, hydrogen, hydroxyl, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkylamino, heterocyclic or heteroaryl.

This invention discloses a method for constructing a macromolecular model of Hami oil-rich coal and its application. The molecular formula and functional group characteristics of the coal sample are determined through elemental analysis and infrared spectroscopy. A planar structural model is constructed using the Wiser model framework, and a stable configuration is obtained after geometric optimization. Finally, a pyrolysis reaction model containing multiple molecules is constructed through stacking. Targeting the high-oxygen and high-cycloalkane structural characteristics of Hami oil-rich coal, a C1... 128 H 82 NO 16 and C 111 H 88 NO 28 Two precise models were used, and the accuracy of the calculated infrared spectra was verified by comparing them with experimental spectra. ReaxFF molecular dynamics simulations were performed using this model, revealing the influence of different heating rates and pyrolysis temperatures on product distribution. The optimal simulation temperature and critical values ​​for pyrolysis rate control were determined, and the difference in ethylene formation pathways between alkyl-rich coal and ether-rich coal was analyzed. This invention fills the gap in precise models for Hami oil-rich coal, providing key theoretical basis and parameter guidance for optimizing pyrolysis processes, achieving targeted regulation, and improving energy efficiency.

The invention discloses a substituted benzo [d] oxazole compound as shown in a general formula (I) as well as a preparation method and application of the substituted benzo [d] oxazole compound. The compound has a benzo [d] oxazole-pyridine skeleton structure, in which: R is selected from C-Cbranched alkyl sulfinyl or C-Ccycloalkyl sulfinyl, preferably isopropyl sulfinyl; r is C-Calkyl; and R is C-Ccycloalkyl. According to the method, a platform preparation route is adopted, a sulfoxide center construction step is placed at the synthesis end, and the system temperature is maintained at 0-10 DEG C (preferably 1-3 hours) by accurately regulating and controlling the dosage (1.05-1.2 equivalents) of an oxidant and controlling the dropping speed, so that the generation (the content lt is 0.5%) of a sulfone byproduct is effectively inhibited, and the stereoselectivity control of the chiral center is realized. A biological activity test result shows that the compound has excellent insecticidal activity on agricultural pests such as brown planthopper, the LC value of the compound can be as low as 1.85 mg / L, the physicochemical property of the compound is suitable for preparation processing, and the compound can be widely applied to prevention and control of the agricultural pests.

The invention discloses mineral oil type transformer oil with low pour point and high gassing resistance and a preparation method thereof. The invention discloses mineral oil type transformer oil with low pour point and high gassing resistance. The mineral oil type transformer oil is prepared by blending the following components in percentage by mass: 10-40% of a first component and 60-90% of a second component, wherein the pour point of the first component is less than-25 DEG C, the kinematic viscosity at 40 DEG C is 8-11 mm < 2 > / s, the flash point is greater than 135 DEG C, the aromatic carbon rate is 2-5%, the naphthenic carbon rate is not less than 50%, and the gassing property is not higher than + 5 mm < 3 > / min; the pour point of the second component is not higher than-60 DEG C, the kinematic viscosity at 40 DEG C is 7-11 mm < 2 > / s, the flash point is greater than 135 DEG C, and the aromatic carbon rate is less than 1%. The pour point of the transformer oil is lower than-50 DEG C, and the gassing property is lower than + 10 mm < 3 > / min, so that the transformer oil can simultaneously meet the standard requirements of GB 2536-2011 and IEC60296: 2020, and can meet the use requirements of power equipment on low-temperature startability and long-term safe and stable operation in a special environment.

The present invention relates to a process for the preparation of unsubstituted or at least monosubstituted cycloalkanones by electrochemically oxidizing unsubstituted or at least monosubstituted saturated alicyclic hydrocarbons in the presence of inorganic or organic nitrates in an electrolytic cell in a reaction medium in the presence of oxygen.

The present invention relates to a chiral iridium hydride complex comprising a) a chiral (P, N)-ligand and b) a stabilized ketene ligand of formula (I), wherein R1 is selected from the group consisting of hydrogen, a C1-C500-alkyl group, a C2-C500-alkenyl group, a C1-C500-alkoxy group, a C2-C500-alkenyloxy group, a C1-C500-alkylamino group, a C2-C500-alkenyl amino group, a di-(C1-C500-alkyl) amino group, a di-(C2-C500-alkenyl) amino group, a N-(C1-C500-alkyl)-N-(C2-C500-alkenyl) amino group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyloxy group, a C3-C8-cycloalkylamino group, a N-(C1-C500-alkyl)-N-(C3-C8-cycloalkyl) amino group, and a pharmaceutically acceptable salt thereof; a C6-C14-aryl group, which may be substituted as further defined in the specification; r1a is selected from hydrogen, C1-C6-alkyl, C1-C6-alkylcarbonyl, or R1a and R1 together with the carbon atom to which R1a is attached and the carbonyl to which R1 is attached form a C5-C7-cycloalkanone ring wherein the C5-C7-cycloalkanone ring is unsubstituted or substituted by 1 to 4 substituents independently selected from C1-C6-alkyl and benzylidene, wherein the benzylidene group is unsubstituted or substituted by 1 to 5 substituents independently of one another selected from the group consisting of halogen, a C1-C500-alkyl group, a C1-C500-alkoxy group, a C1-C500-haloalkyl group, and a C1-C500-haloalkoxy group; r2 is selected from hydrogen, a C1-C500-alkyl group, a C1-C500-alkoxy group, a C1-C500-alkylamino group, a di-(C1-C500-alkyl) amino group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyloxy group, a C3-C8-cycloalkylamino group, an N-(C1-C500-alkyl)-N-(C3-C8-cycloalkyl) amino group, a C6-C14-aryl group, which may be substituted as further defined in the specification; and arrow represents a bond attached to an iridium atom; the present invention relates to chiral iridium hydride complexes, and to a method for producing optically active 4-substituted 1, 2, 3, 4-tetrahydroquinolines by enantioselective hydrogenation of the corresponding 4-substituted 1, 2-dihydroquinolines in the presence of such chiral iridium hydride complexes.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

The present application relates to a beta-lactamase inhibitor intermediate co-crystal or salt, a preparation method and application thereof, and belongs to the technical field of pharmaceutical chemical engineering. The structural formula is as follows: R2 represents benzyl or allyl; R3 represents an alkylamine group with a protective group, a cycloalkylamine group, an aromatic amine group, and a derivative amine group. The preparation method comprises the following steps: dissolving compound I in a solvent A, adding a base solution to react under the condition of less than 0℃, then adding an acid to adjust the pH to be acidic, adding a solvent B to extract the product, separating the layers, and leaving the organic phase; and then adding a beta-lactamase inhibitor side chain R3H to react. The beta-lactamase inhibitor is prepared by using the intermediate co-crystal or the new salt, the purity is greater than 99.90%, the pharmaceutical quality standard of the crude drug is met, the process operation is safe, simple, convenient, green and environment-friendly; the atom economy, the selectivity, the purity and the yield of each step reaction are high, and the production can be enlarged.

The invention belongs to the field of chemical synthesis, and particularly relates to a hydroxylamine compound containing an aryl allyl structure as well as a synthesis method and application of the hydroxylamine compound. The structure of the hydroxylamine compound is shown as a formula (I), and in the formula (I), R1 is selected from unsubstituted alkyl, cycloalkyl, naphthyl, heteroaryl or substituted or unsubstituted phenyl; r2 is selected from substituted or unsubstituted phenyl; the synthesis method comprises the following steps: by taking nitrone and boric acid as raw materials, efficiently synthesizing through a boron migration reaction under the catalysis of R-1, 1 '-co-2-naphthol. The synthesis method has the characteristics that a metal catalyst is not needed, the operation is simple and convenient, the organic boric acid is easy to obtain and environment-friendly, the reaction condition is mild, the substrate application range is wide, the yield is medium to good and the like, and a new thought is provided for synthesis of the hydroxylamine compound. In-vitro experiments show that the compound has remarkable proliferation inhibition activity on A549, HeLa and MV-411 tumor cells, and has the development potential of antitumor drugs.

This invention provides compounds of general formula (I) or pharmaceutically acceptable salts, precursors, solvates thereof, and their use in the preparation of diagnostic drugs for diabetic nephropathy, wherein (I) X is selected from carbon or nitrogen; R 1 Selected from hydrogen or alkyl; R 2 It is one or more substituents on the benzene ring or pyridine ring, R 2 Independently selected from one or more of hydrogen, halogen, hydroxyl, cyano, nitro, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C6 cycloalkoxy, C1-C6 alkylamino, C3-C6 cycloalkylamino, halo-C1-C6 alkyl, halo-C3-C6 cycloalkyl, halo-C1-C6 alkoxy, halo-C3-C6 cycloalkoxy, halo-C1-C6 alkylamino, halo-C3-C6 cycloalkylamino, C6-C8 aryl or C5-C8 heteroaryl, and R 2 At least one atom of these substituents, or the entire substituent, is replaced by a radioactive nuclide. The diagnostic drugs and methods for diabetic nephropathy of the present invention are non-invasive diagnostic techniques, with advantages such as less discomfort for the subjects and fewer contraindications.

The present invention relates to a process for the preparation of an oxa-bicycloalkene from a hydroxyalkyl cycloalkanone in the presence of an acid and using a thin film evaporator and the use of a thin film evaporator to conduct such a process.

This invention belongs to the field of chemical medicine, specifically relating to a phenylpropanoid compound, its preparation method, and its application. The phenylpropanoid compound specifically refers to the compound, solvate, optically pure isomer, stereoisomer, or pharmaceutically acceptable salt thereof, or mixtures thereof, represented by general formula (Ⅰ), wherein X is selected from O or N; R1, R2, R3, R4, and R5 are the same or different, and are independently selected from hydrogen, hydroxyl, halogen, alkoxy, and alkylthio groups; R 13 Selected from hydrogen or C1-C4 alkyl, or R 13 Connect R5 to form a loop; R 14 The compounds are selected from cycloalkyl groups with 5-6 substituted carbon atoms. The phenylpropanoid compounds synthesized in this invention exhibit significant inhibitory effects on glioma cells, and their inhibitory effect is superior to that of the positive control drugs temozolomide and the original chlorogenic acid. Simultaneously, some of the synthesized phenylpropanoid compounds significantly improve neuronal cell survival rates, and their protective effect is superior to that of the positive control drug edaravone, demonstrating potential for treating stroke.

The application belongs to the field of mechanical color-changing materials, and relates to a tetraphenyl ethylene-containing cycloalkane and a preparation method thereof, and a mechanical response luminescent polymer based on AIE supramolecular cycloalkane and application. The structure of the tetraphenyl ethylene-containing cycloalkane is shown in formula I: in formula I, A is a tetraphenyl ethylene structural unit, m is an integer of 2-20, and n is an integer of 2-20. In the application, AIEgens is designed as a cycloalkane, and the mechanical force only changes the conformation of the ring, that is, only the intramolecular interaction is changed so as to change the luminescent intensity of the molecule. The luminescent characteristics are independent of the AIEgens concentration and the morphology of the material. The mechanical response luminescent polymer based on AIE supramolecular cycloalkane has stronger applicability.

This invention discloses a broad-spectrum antibacterial agent based on azide compounds and its application in the control of soil-borne agricultural diseases, belonging to the field of agricultural biotechnology. The antibacterial agent contains azide compounds with the general formula R1-AZ (AZ being an azide group, and R1 selected from specific substituents such as alkyl and cycloalkyl groups), specifically including various compounds such as phosphate esters, alkyl and cycloalkyl groups, carbonate / ether / alcohol groups, etc., which can be obtained through isolation from secondary metabolites of *Fusarium graminearum* or chemical synthesis. It exhibits significant inhibitory activity against various difficult-to-control soil-borne pathogens such as *Fusarium oxysporum* and *Blastomyces oryzae*, completely inhibiting the growth of target strains at concentrations of 30-100 ppm, and also showing good control efficacy in field trials. This invention solves the problems of strong resistance to existing chemical pesticides and unstable biological control effects, providing a new, efficient, and environmentally friendly solution for the control of agricultural diseases.

The present invention relates to the use of bis (benzylidene) cycloalkanones and heterocyclic analogs thereof in human and veterinary medicaments for the treatment of diseases caused by the presence or elevated level of intracellular metastable proteins, imbalanced protein homeostasis and proteotoxic stress, typically proteinopathies, such as human and veterinary diseases. In particular, they are useful in the treatment of neurodegenerative diseases (e.g. Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Kenyi's disease (KD), Huntington's disease (HD), Crash's disease (CJD), spinal cerebellar ataxia (SCA), dentonucleus red-nuclear and palliary-body atrophy, transthyretin familial amyloid polyneuropathy), systemic amyloidosis, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, neurodegenerative disease, and the like. The invention also relates to the use of the pharmaceutical composition for treating diabetes mellitus. In addition, the present invention provides novel bis (benzylidene) cycloalkanones.

The invention belongs to the technical field of proton exchange membrane fuel cells, and provides catalyst slurry and a preparation method thereof, and a membrane electrode and a preparation method and application thereof. The catalyst slurry provided by the invention comprises a Nafion ionomer, a platinum carbon catalyst, naphthenone (including one or more of cyclobutanone, cyclohexanone and cyclooctanone), water and isopropanol. According to the invention, cycloalkanone is added, and cycloalkanone can form a stable structure with water and Pt in the platinum-carbon catalyst through specific adsorption, which is specifically embodied in that on one hand, cycloalkanone and water molecules form hydrogen bonds to capture water and participate in construction of a proton transmission channel; on the other hand, the naphthenone and Pt in the platinum-carbon catalyst interact to firmly fix water molecules around the Pt, so that when the overall temperature exceeds the vaporization temperature of the water, the naphthenone molecules cannot be lost due to vaporization of the water, the structural damage cannot be caused, and the constructed proton transmission channel is stabilized.

The invention discloses a preparation method of bio-based naphthenic diamine and bio-based naphthenic diamine, and belongs to the technical field of fine chemical synthesis. The preparation method of the bio-based naphthenic diamine comprises the following steps: (1) mixing C10-C20 bio-based diene cycloolefin, a first catalyst and synthesis gas, and reacting to obtain a reaction system S1 containing a C12-C22 naphthenic dicarboxaldehyde intermediate; and (2) mixing the S1 with ammonia gas, a second catalyst and organic weak acid for reaction to obtain the C12-C22 bio-based naphthenic diamine. According to the preparation method disclosed by the invention, bio-based diene cycloolefin is taken as a starting raw material, and through selection of a catalyst and regulation and control of process conditions, side reactions are effectively inhibited, efficient series connection of hydroformylation and reductive ammoniation is realized, the production process is simplified, the yield and purity of the product are improved, and green preparation of naphthenic diamine is realized; the production cost is reduced, and the method has a good industrial application prospect.